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Background: The optimization of protein production is a complex and challenging problem in biotechnology.
Different techniques for transcription, translation engineering and the optimization of cell culture conditions have
been used to improve protein secretion, but there remain many open problems involving post-translational
modifications of the secreted protein and cell line stability.
Results: In this work, we focus on the regulation of secreted protein specific productivity (using a recombinant
human immunoglobulin G (IgG)) by controlling the expression of the spliced form of human X-box binding protein
(XBP-(s)) in Chinese hamster ovary cells (CHO-K1) under doxycycline (DOX) induction at different temperatures. We
observed a four-fold increase in specific IgG productivity by CHO cells under elevated concentrations of DOX at
30°C compared to 37°C, without detectable differences in binding activity in vitro or changes in the structural integrity
of IgG. In addition, we found a correlation between the overexpression of human XBP-1(s) (and, as a consequence,
endoplasmic reticulum (ER) size expansion) and the specific IgG productivity under DOX induction.
Conclusions: Our data suggest the T-REx system overexpressing human XBP-1(s) can be successfully used in CHO-K1
cells for human immunoglobulin production.
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The optimization of the production of secreted proteins,
such as therapeutic monoclonal antibodies (mAbs), is
still a challenging problem in pharmaceutical biotech-
nology. Although biopharmaceutical products can be
produced by many host cell systems, eukaryotic cells are
preferred due to their ability to correctly process and
modify human proteins. The primary goal is to establish
the ideal combination of a rapid accumulation of pro-
ductive biomass and the maintenance of cell viability for
as long as possible. Many different strategies have been
considered for improving both cell viability and the
productivity of recombinant proteins, including mAbs.
These strategies include physiological optimization and
genetic and metabolic engineering [1,2].* Correspondence: gulis001@gmail.com
Institute of Biological Sciences, Department of Cell Biology, University of
Brasilia, Campus Universitário Darcy Ribeiro, Brasília, DF 70910-900, Brazil
© 2014 Gulis et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.The most common problem during the optimization
of protein production is an error in protein folding in
the endoplasmic reticulum (ER). The inhibition of pro-
tein folding activates the unfolded protein response
(UPR), which is a signal transduction network. Over-
coming UPR is one of the many strategies for optimizing
protein productivity. For instance, protein production
has been tested under the expression of survival proteins
that play important roles in UPR, including B-cell
lymphoma protein 2 (bcl-2), B-cell lymphoma-extra-
large protein (bcl-XL) [3-5], caspase inhibitors [6] and
molecular chaperones/heat shock proteins (HSP70) [7].
The role of the spliced form of X-box binding protein
(XBP-1(s)) (which plays an important role in regulation
processes, such as physical expansion of the ER, increas-
ing the mitochondrial mass and function, increasing the
cell size and enhancing total protein synthesis) in opti-
mizing protein production has also been studied [8].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mammalian cells by overexpressing the transcription
factor XBP-1(s) was successful in CHO cells; the pro-
duction of the secreted proteins alkaline phosphatase
(SEAP) and alpha-amylase (SAMY) was enhanced upon
XBP-1(s) overexpression [9], as was the production of
antibody [10]. However, these studies have shown that
using overexpression systems without regulation leads to
cell apoptosis due to the accumulation of the produced
proteins [11].
To overcome accumulation-induced apoptosis, other
strategies have been applied to regulate the protein
production, such as the use of induction systems. For
instance, tetracycline has been used to optimize the
overexpression of glycosyltransferases under the control of
the Tet on/off system in CHO cells, but unfortunately, a
high expression of glycosyltransferases still led to growth
inhibition [12]. Furthermore, interesting work using the
same expression system has been conducted to control
the overexpression of human transferrin (hTf) in human
embryonic kidney (HEK-293) cells. That study found fa-
vorable concentrations of tetracycline at which the overex-
pression of hTf was optimal, but again, the high levels of
expression limited the cell viability. Such impairment
might have been a consequence of the overexpression of
the protein of interest, which might have altered the qual-
ity of this cell product or even been toxic to the cells [13].
Some studies have attempted to investigate the effect of
the expression of an ER-resident molecular chaperone,
protein disulfide isomerase (PDI), on the specific produc-
tion levels of thrombopoietin (TPO) and antibody (Ab) in
Chinese hamster ovary cells. Mohan and colleagues used
the Tet-off system (in the absence of tetracycline) to regu-
late PDI, TPO and Ab expression in CHO cells under
doxycycline (DOX; a chemical analogue of tetracycline)
induction. However, only a small increase in antibody
production was observed, and the production of TPO
was not affected by PDI expression [14].
Moreover, the optimization of protein production in
CHO cells cultured at different temperatures has been
addressed. For instance, lowering the temperature from
37°C to 33°C increased the production of erythropoietin
(EPO) by approximately four-fold, but at the same time, a
low cultivation temperature suppressed cell growth [15].
In addition, a temperature reduction from 37°C to 33°C in
the culture of a CHO cell line producing recombinant
human granulocyte/macrophage colony-stimulating fac-
tor (CHO-K1-hGM-CSF) led to a reduced growth rate,
increased cell viability, improved cellular protein pro-
duction and decreased cell metabolism [16]. One study
on the optimization of protein production at 32°C also
demonstrated that the specific growth rate of CHO
cells producing human mAb decreased by 30–63% at
32°C compared to 37°C. However, the specific antibodyproductivity of these cells was significantly enhanced at
32°C [17]. Lowering the cultivation temperature even
more, from 37°C to 30°C, caused growth arrest associated
with a 1.7-fold increase in the specific production of se-
creted alkaline phosphatase (SEAP) in CHO cells [18].
In this context, we attempted to optimize the specific
IgG productivity under different culture temperatures
and by regulating the overexpression of apoptotic human
protein XBP-1(s) using the T-REx™ system (Invitrogen,
Carlsbad, CA, USA). The applied T-REx™ system con-
tains a regulatory plasmid (pcDNA6/TR), which encodes
the tetracycline repressor, and an inducible expression
plasmid (pcDNA™4/TO/myc-His A) with a tetracycline
inductor for expression of the gene of the interest (xbp-
1(s)). Co-transfected together, these plasmids created a
network to regulate XBP-1(s) expression under DOX
induction. We cloned xbp-1(s) into the T-REx™ system
to control its expression with DOX. Then, we trans-
fected the obtained T-REx™-XBP-1(s) system into stably
IgG-producing CHO cells and selected stable clones of
this system expressing IgG-T-REx-XBP-1(s) to control
specific IgG productivity under DOX induction (Figure 1).
We determined the optimal concentration of DOX and
the temperature at which IgG-T-REx-XBP-1(s) cells pro-
duced the maximal amount of IgG without a significant
inhibition of cell growth. Moreover, cells treated with DOX
for seven days recovered viable cell density to the level of
non-treated cells after DOX was washed out from the cell
system, and their specific IgG productivity dropped to the
basal level. Furthermore, we studied the dependence of spe-
cific IgG productivity and viable cell density on the overex-
pression of XBP-1(s) and ER size expansion.
Methods
Cell lines and media
The CHO-K1 (ATCC®CCL-61™) and Raji (ATCC®CCL-
86™) cell lines were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA). CHO-
K1 cells were grown and maintained at 37°C or 30°C
with 70% humidity and 5% CO2 in HAM F12 media
(Gibco, Big Cabin, OK, USA) supplemented with 2%
fetal bovine serum (FBS, Gibco, Big Cabin, OK, USA)
and were used in experiments on protein production.
Raji cells were grown and maintained at 37°C with70%
humidity and 5% CO2 in RAMP media (Gibco, Big
Cabin, OK, USA) supplemented with 10% FBS and were
used in FACS direct ligation experiments.
Plasmids and cloning
pCOMIRES HIL anti-CD20 is a tricistronic vector that
encodes both the heavy and the light chains of an anti-
CD20 antibody along with a neomycin resistance gene
under the control of a synthetic CMV promoter. This
vector was transfected into CHO-K1 cells to obtain IgG
Figure 1 Schematic representation of the DOX-regulated T-Rex™ overexpression XBP-1(s) system. The overproduction of IgG as a result of
the XBP-1(s) overexpression and ER size expansion under DOX induction (on DOX induction) (A). The repression of XBP-1(s) overexpression and
ER size expansion resulted in the repression of overproduction of IgG in the absence of DOX (off DOX induction) (B).
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sequence was chemically synthesized by GeneScript (Piscat-
away, NJ, USA). The restriction enzymes Hind III and
BamH I (Fermentas, Ontario, Canada) were used to obtain
the xbp-1(s) insert and then clone it into the inducible
expression plasmid pcDNA™4/TO/myc-His A from the
Invitrogen T-REx™ system (Invitrogen, Carlsbad, CA, USA).
This plasmid was used to co-transfect IgG-producing stable
clones of CHO cells along with the regulatory plasmid
pcDNA6/TR (Invitrogen, Carlsbad, CA, USA). To confirm
xbp-1(s) cloning, XL1-blue bacterial cells (Stratagene, La
Jolla, CA, USA) were transformed with ligated DNA.
Ampicillin (Sigma, Ronkonkoma, NY, USA)-selected
colonies were isolated and processed for DNA extrac-
tion and purification, which was performed using a
QIAprep Miniprep Kit (Qiagen, Valencia, CA, USA).
Restriction analysis and sequencing (using CMV for-
ward primer 5′-CGCAAATGGGCGGTAGGCGTG-3′
and BGH reverse primer 5′-TAGAAGGCACAGTCG
AGG-3′) confirmed the cloning of the xbp-1(s) insert.
Transfection with pCOMIRES anti-CD20 DNA (IgG-encoding
plasmid) into CHO cells and generation of stable
IgG-producing cells
The transfection of pCOMIRES HIL anti-CD20 plasmid
(encoding an anti-CD 20 (IgG) antibody, a secretableprotein with molecular weight 150 kDa (two light
chains, each with molecular weight 25 kDa, and two
heavy chains, each with molecular weight 50 kDa)) into
CHO cells was performed using a PolyPlus (JetPrime,
New York, NY, USA) kit in six-well test plates (TPP,
San Diego, CA, USA) according to the manufacturer’s
instructions. The clones harboring the pCOMIRES HIL
anti-CD20 transgene were selected from a mixed popula-
tion by the single-cell dilution method. Geneticin (Roche,
Gaillard, France) was used for selection at 800 μg/mL.
Transfection with the T-REx™ -XBP-1(s) system into stable
IgG-producing clones of CHO cells and generation of
stable double clones (IgG-T-REx-XBP-1(s) cells)
The co-transfection of T-REx-xbp-1(s) plasmid (encoding a
spliced form of human apoptotic XBP-1 protein with pre-
dicted molecular weight 40 kDa) along with regulatory
plasmid pcDNA6/TR into one of the stable IgG-producing
clones was performed using a PolyPlus (JetPrime, New
York, NY, USA) kit according to the manufacturer’s
instructions in six-well test plates (TPP, San Diego, CA,
USA). Blasticidin (Sigma, Ronkonkoma, NY, USA) and
Zeocin (Sigma, Ronkonkoma, NY, USA) were added to
a final concentration of 0.5 μg/mL and 50 μg/mL,
respectively. The selective markers encoded by regulatory
plasmid pcDNA6/TR and expression plasmid pcDNA™4/
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respectively.
Doxycycline induction
Selected IgG-T-REx-XBP-1(s) cells (after the first trans-
fection, IgG clones; after the second, co-transfection,
T-REx-XBP-1(s) clones) were induced by DOX at differ-
ent concentrations: 0 μg/mL for control, 0.1 μg/mL,
0.5 μg/mL and 1 μg/mL. We used these concentrations
because we found out that 5 μg/ml and 7.5 μg/ml of
doxycycline completely inhibits cells growth for clones
and wild type CHO-K1 cells. DOX induction was per-
formed 24 hr after IgG-T-REx-XBP-1(s) cells seeding at a
uniform cell density (0.5 × 105 cells/mL) in tissue culture
flasks (75 cm2, TPP, San Diego, CA, USA) and then incu-
bated for seven days at 37°C or 30°C. All cultures reached
at least 80% under these conditions. Samples were col-
lected for viable cell density, Ab detection by ELISA,
nuclear extract isolation and ER staining. Half of the
cells in each group continued to grow for seven more
days in DOX-free medium after DOX wash-out. Inde-
pendently, IgG-T-REx-XBP-1(s) cells were incubated for
42 days at 30°C (150 cm2 flasks, TPP, San Diego, CA,
USA) with or without 1 μg/mL DOX. In all DOX induc-
tion experiments, DOX was added (at an appropriate
concentration) every three days to the cell culture.
Induction experiments were performed twice in dupli-
cate (four independent culture samples per group).
Viability assay
The viable cell density of the IgG-T-REx-XBP-1(s) cells
were tested under different DOX concentrations (0 μg/
mL, 0.1 μg/mL, 0.5 μg/mL or 1 μg/mL) every day during
seven days of cell growth at 37°C and 30°C. Seeding was
performed at a uniform cell density (0.06 × 105 cells/
mL) in six-well tissue culture plates (TPP, San Diego,
CA, USA). At the seventh day all cultures reached at
least 80% under these conditions. In addition, the viable
cell density of IgG-T-REx-XBP-1(s) cells was tested on
the seventh day of growth with DOX and on the seventh
day after wash-out in DOX-free medium. In addition,
IgG-T-REx-XBP-1(s) cells were tested every seventh day
during 42 days of cell growth under 1 μg/mL DOX (or
0 μg/mL as control) at 30°C. The viable cell density was
measured using the trypan blue (Sigma, Ronkonkoma,
NY, USA) exclusion method with a hemocytometer and
light microscope for manual cell counting. Every viable
cell density experiment was performed twice in duplicate
(single determination from each of two independent cul-
ture samples per group in two independent experiments).
ELISA
The supernatants of IgG-T-REx-XBP-1(s) cells in the pres-
ence or absence of DOX were collected every seventh dayof 37°C or 30°C growth for two weeks or every seventh
day for six weeks and processed for analysis by enzyme-
linked immunosorbent assay (ELISA) (duplicate deter-
mination from each of two independent culture samples
per group in two independent experiments). The Lunc/
Maxisorp Immunoplate (Thermo Scientific, Waltham,
MA, USA) was incubated with primary antibody (goat
anti-human IgG (H + L), 1:3000 dilution; Thermo Scien-
tific, Waltham, MA, USA) and blocked with 3% fat-free
dehydrated milk solution. After blocking and washing
the plate, the supernatants were applied to the plate and
incubated for 2 hr. The plate was washed again, and
secondary antibody (anti-human IgG Fc-specific, alka-
line phosphatase-conjugated, produced in goat, 1:3000
dilution; Sigma, Ronkonkoma, NY, USA) was applied
for 1 hr. The plate was washed again, and at the end of
the procedure, the signal of absorbance was read at
405 nm by a microplate reader (ELx800 96-well Micro-
plate Reader, MTX Lab Systems, Inc., Vienna, VA, USA)
after 4-Nitrophenyl phosphate disodium salt solution
(pNPP) (Invitrogen, Carlsbad, CA, USA) addition. In
addition, human IgG (whole molecule; Thermo Scien-
tific, Waltham, MA, USA) was used in different concen-
trations as a control on the same plate.Isolation and purification of produced proteins
The IgG produced under different temperature condi-
tions by IgG-T-REx-XBP-1(s) cells was purified on the
HiTrap™ Protein A HP 1 mL (GE Life Sciences, Pitts-
burgh, PA, USA) column. The column was first equili-
brated with 10 mL Protein A IgG Binding Buffer
(Thermo Scientific, Waltham, MA, USA) at a rate of
1 mL/min. Then, the supernatant from IgG-T-REx-XBP-
1(s) cells was applied to the equilibrated column. The
column was washed with 30 mL Protein A IgG Binding
Buffer (Thermo Scientific, Waltham, MA, USA). Then,
the protein was eluted with 50 mL IgG Elution Buffer
(Thermo Scientific, Waltham, MA, USA), and 2 mL per
fraction was collected. Fractions were neutralized with
Tris–HCl pH 9.0. The Ab present in the fractions was
immunodetected in a dot blot assay. Five microliters of
each fraction was directly pipetted onto a nitrocellulose
Hybond-C Extra membrane (Amersham® Bioscience,
Piscataway, NJ, USA). The membrane was blocked with
3% fat-free milk solution and incubated with anti-human
IgG (Fc-specific, alkaline phosphatase-conjugated, pro-
duced in goat, 1:3000 dilution) (Sigma, Ronkonkoma,
NY, USA), and the proteins were revealed using a BCIP/
NBT substrate Kit (Invitrogen, Carlsbad, CA, USA). The
Ab-containing fractions were selected for dialysis, which
was performed using a Centricon YM-50 (Amicon Bio-
separations, Billerica, MA, USA) in PBS buffer (10 mM
NaH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4).
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Anti-CD20 antibody was also detected by western blot-
ting. Five hundred nanograms of IgG sample was loaded
in each well of a Bis-Tris gel (NuPAGE® Novex 4-12%
Bis-Tris Gel, Invitrogen, Carlsbad, CA, USA) and sepa-
rated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) according to the manu-
facturer’s instructions. The proteins were transferred to
the Hybond-C Extra nitrocellulose membrane (Amersham®
Bioscience, Piscataway, NJ, USA) and blocked in 3%
fat-free milk PBS solution. The immunodetection was
performed using anti-human IgG (Fc-specific, alka-
line phosphatase-conjugated, produced in goat (1:3000
dilution) (Sigma, Ronkonkoma, NY, USA) with a BCIP/
NBT substrate Kit™ (Invitrogen, Carlsbad, CA, USA).
XBP-1(s) was also probed by western blotting. The nu-
clear extracts from the IgG-T-REx-XBP-1(s) cells were
prepared as described by Becker and colleagues [10].
Briefly, the nuclear extracts were prepared from 5×106
cells/per sample and equal volumes of nuclear extracts
were loaded into a Bis-Tris gel (NuPAGE® Novex 4-12%
Bis-Tris Gel, Invitrogen, Carlsbad, CA, USA), and SDS-
PAGE was performed according to the manufacturer’s
instructions. Samples were transferred to the Hybond-C
Extra nitrocellulose membrane (Amersham® Bioscience,
Piscataway, NJ, USA), and after blocking with 3%
fat-free milk PBS solution, rabbit anti-human-XBP-1(s)
(1:1000 dilution; Sigma, Ronkonkoma, NY, USA) was
added, followed by alkaline phosphatase-conjugated
anti-rabbit IgG incubation (1:1000 dilution; Sigma,
Ronkonkoma, NY, USA). The proteins were revealed
using a BCIP/NBT substrate Kit™ (Invitrogen, Carlsbad,
CA, USA).Fluorescence-activated cell sorting (FACS)-ER staining
The IgG-T-REx-XBP-1(s) cells that were grown for seven
days under DOX induction and those that were grown
for one more week after wash-out were collected at
3×105 cells/per staining and washed with HBSS buffer
(140 mM NaCl, 4.7 mM KCl, 1 mM MgCl2, 1.5 mM
CaCl2, 10 mM glucose, 10 mM HEPES, pH 7.4). After
washing with HBSS buffer, the cells were labeled with
250 nM of ER-Tracker™ Green Dye (ER-Tracker™ Green
Dye for Live-Cell Endoplasmic Reticulum, Molecular
Probes, Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s manual. The samples were washed
again with HBSS buffer and analyzed using a BD FACS
Verse flow cytometer (BD Bioscience, San Jose, CA,
USA). Ten thousand events were collected per sample
using no gate for acquisition. The dead cells were not
excluded in the analysis. We used BD FACSuite to data
acquisition. The experiment was performed twice in
duplicate.FACS direct ligation assay
Raji cells were grown for five passages as described
above, collected and resuspended in 1 part RAMP media
with 10% FBS and 1 part FACS buffer (PBS supple-
mented with 2% FBS) at 3×106 cells/well in a 96-well
plate (TPP, San Diego, CA, USA). After centrifugation,
the cells were blocked with FcR blocking reagent
(MACS, Biotec, Bergisch Gladbach, Germany) on ice for
30 minutes according to the manufacturer’s instructions.
Purified and dialyzed IgG samples, which were produced
by IgG-T-REx-XBP-1(s) cells at 37°C and 30°C, and com-
mercial IgG (rituximab, MabThera, Genetech Inc., South
San Francisco, CA, USA) as a positive control were
added at 100 ng per well. Samples were incubated on ice
for 1 hr and centrifuged after the addition of FACS buf-
fer. The cells were washed twice with FACS buffer and
incubated with mouse FITC anti-human IgG (BD Phar-
mingen™, BD Biosciences, San Jose, CA, USA) according
to the manufacturer’s manual. The cells were incubated
on ice for 30 minutes in the dark, washed again twice
with FACS buffer and processed for fluorescence inten-
sity measurements using a BD FACS Verse flow cyt-
ometer (BD Bioscience, San Jose, CA, USA). Each
experiment was performed twice in duplicate.
Results and discussion
Viability and IgG production under induction with DOX in
IgG-T-REx-XBP-1(s) cells cultivated at 37°C and 30°C
To establish a DOX-regulated XBP-1(s) cell line, we first
created stably IgG-producing clones of CHO cells by
transfecting the pCOMIRES HIL anti-CD20 plasmid
into CHO-K1 cells. Then, IgG-CHO clones selected with
800 μg/mL of Geneticin were co-transfected with the
T-REx-XBP-1(s) system and processed for second selec-
tion using 0.5 μg/mL of blasticidin and 50 μg/mL of
Zeocin. From these double clones harboring both pCO-
MIRES HIL anti-CD20 and T-REx-XBP-1(s) system plas-
mids, we chose one out of 20 for DOX induction at
different concentrations (0 μg/mL (control), 0.1 μg/mL,
0.5 μg/mL or 1 μg/mL) and grew them at 37°C or 30°C.
Every day, cells were collected to monitor viable cell
density. We found that the viable cell density of the
IgG-T-REx-XBP-1(s) cells grown at 37°C under 1 μg/mL
or 0.5 μg/mL DOX was slightly lower compared to the
control and to the cells with 0.1 μg/mL DOX induction
(Figure 2A). Moreover, the viable cell density of IgG-T-
REx-XBP-1(s) cells grown at 37°C without DOX or with
0.1 μg/mL DOX was 1.25-fold higher compared to the
cells grown at 30°C (Figure 2A and 2B). These data agree
with several previous studies [15-18]. Moreover, the
viable cell density of IgG-T-REx-XBP-1(s) cells grown at
37°C under 1 μg/mL DOX induction was increased by
20.5% compared to cells incubated at 30°C under the
same DOX concentration (Figure 2A and 2B). Thus,
AB
C
Figure 2 Viable cell density of IgG-T-Rex-XBP-1(s) cells cultured at 37°C (A) or 30°C (B) and their specific IgG productivity at 37°C and
30°C (C) under induction with 0 μg/mL (control), 0.1 μg/mL, 0.5 μg/mL and 1 μg/mL DOX. Error bars represent the standard deviation of
the mean of two readings from each of two independent culture samples per group in two independent experiments, n = 4.
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or without DOX compared to those at 37°C.
The supernatants from all cells were collected after
seven days of induction and tested by ELISA to determinetheir IgG yields. The specific IgG productivity depended
on the concentration of DOX: under 0.5 μg/mL and 1 μg/
mL DOX, the increase of specific IgG productivity was
40% and 66%, respectively, compared to the basal level of
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(Figure 2C). These data demonstrate that IgG-T-REx-XBP-
1(s) cells produced three-fold more IgG compared to un-
treated cells, even at low viable cell density. At 0.1 μg/mL
DOX, there was no improvement in specific IgG productiv-
ity at 37°C. Moreover, the data from ELISA indicate that
protein production in the cells incubated at 30°C increased
four-fold and three-fold under 1 μg/mL and 0.5 μg/mL
DOX, respectively. Once more, induction at a low concen-
tration of DOX (0.1 μg/mL) did not increase specific IgG
productivity at 30°C, as above at 37°C. In contrast, the
specific IgG productivity by IgG-T-REx-XBP-1(s) cells
at 30°C increased by 31.5% and 43.5% compared to in-
duction at 37°C under 1 μg/mL and 0.5 μg/mL DOX
concentrations, respectively (Figure 2C). However, we
did not detect any effect of low temperature on specific
IgG productivity per se (without the induction of DOX).
Tigges and Fussenegger [9] reported the same lack of
effect in CHO cells expressing SEAP, whereas other
authors reported an increase in the production of differ-
ent proteins at low temperature and with no inductor
[15-18]. These deviations in experimental results may
be due to differences in the proteins and cell lines used
in these studies. In conclusion, our data demonstrate a
successful improvement of specific IgG productivity
using 1 μg/mL DOX in IgG-T-REx-XBP-1(s) cells at 30°C.
Effect of XBP-1(s) expression and ER size expansion on
protein production in IgG-T-REx-XBP-1(s) cells
To test the hypothesis that XBP-1(s) expression and ER
size expansion indirectly regulate protein production,
IgG-T-REx-XBP-1(s) cells were incubated under different
concentrations of DOX for seven days at 30°C, and then
the same cells were washed with DOX-free medium and
incubated for seven more days at the same temperature in
fresh DOX-free medium. The supernatant was collected
before wash-out and after seven days of incubation in
DOX-free medium and processed for ELISA. ELISA
showed that specific IgG productivity by cells with DOX
(first seven days) increased in a DOX concentration-
dependent manner. The specific IgG productivity by cells
incubated with 1 μg/mL DOX and 0.5 μg/mL DOX
reached four-fold and three-fold that of the untreated cells
(treated (t), Figure 3A). In addition, ELISA demonstrated
that after DOX removal, the specific IgG productivity
returned to the basal level (washed, (w) Figure 3A). More-
over, viability analysis indicated that the growth of the
IgG-T-REx-XBP-1(s) cells under different concentrations
of DOX was slightly inhibited (first seven days, treated (t),
Figure 3B) and then restored to the same level (washed
(w), Figure 3B) as cells that had never been exposed to
DOX (0 μg/mL (t or w), Figure 3B). In addition, IgG-T-
REx-XBP-1(s) cells were used to prepare nuclear extracts,
which were analyzed by western blotting for the immunedetection of XBP (s). Human XBP-1 (s) was overexpressed
in a DOX concentration-dependent manner (first seven
days, on DOX induction, treated (t) Figure 3C), but it was
absent in cells that were washed and incubated in DOX-
free medium for seven days (last seven days, off DOX
induction, washed (w), Figure 3C).
ER expansion was also observed by flow cytometry.
The fluorescence change of ER-Tracker™ was used as a
measure of ER size expansion. In this analysis, cell
staining was more intense in samples treated with 1 μg/
mL or 0.5 μg/mL DOX for seven days (on DOX induc-
tion, treated (t), Figure 4A) than in those treated with
0.1 μg/mL (on DOX induction, treated (t), Figure 4A)
or 0 μg/mL or those that were washed out (w),
Figure 4B). Moreover, the signal from the washed out
cells was equal among different conditions (off DOX
induction, washed (w), Figure 4B), which indicated that
DOX was responsible for a cascade of processes leading
to ER size expansion. In addition, measurements of the
median fluorescence intensity (MFI, Figure 4C) obtained
from FACS analysis showed that the MFI of the cells
treated with 1 μg/mL or 0.5 μg/mL DOX was 2.7-fold or
1.85-fold higher, respectively, than the MFI of non-treated
cells or washed out cells (Figure 4C). Thus, cells under
DOX induction and low temperature grew more slowly
but, at the same time, exhibited a greater increase in
specific IgG productivity. Our data also demonstrate
that the wash-out of DOX from the cells restored their
viable cell density but reduced their specific IgG prod-
uctivity to basal levels. Taken together, our results indi-
cate the optimal conditions for specific IgG productivity
under DOX induction. XBP-1(s) was overexpressed
under induction with DOX, which led to the ER size
expansion, and this resulted in an increase of specific
IgG productivity/secretion. Our findings corroborate
the data obtained by Tigges and Fussenegger, who
reported an increased production of SEAP and SAMY
under the expression of XBP-1(s) and the expansion of
ER and Golgi [9].
Binding activity of the recombinant proteins produced at
different temperatures
To assess its binding activity, the recombinant IgG pro-
duced by cells at different temperatures (37°C and 30°C)
was purified and tested for its ability to recognize CD20
at the cell surface of Raji cells that were subjected to flow
cytometry analysis. FACS analysis indicated no significant
difference in the binding activity of IgG produced by IgG-
T-REx-XBP-1(s) cells at different temperatures under DOX
induction from commercial IgG (rituximab) (Figure 5A).
Moreover, protein samples obtained from the IgG-T-REx-
XBP-1(s) cells at different temperatures under DOX induc-
tion were submitted to western blotting analysis, and the
results did not suggest any differences in structural integrity
AB
C
Figure 3 The specific IgG productivity (A), log of viable cell density (B) and western blot analysis of nuclear extracts (C) from the
IgG-T-Rex-XBP-1(s) cells grown at 30°C under 0 μg/mL, 0.1 μg/mL, 0.5 μg/mL or 1 μg/mL DOX for seven days (treated, t) and from the
same cells seven days after DOX wash-out (washed, w). PL, protein ladder. Error bars represent the standard deviation of the mean of double
determination from each of two independent culture samples per group in two independent experiments, n = 4.
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These data support the use of low-temperature culture
conditions under induction by DOX to increase protein
production without eliminating the binding activity and
structural integrity of the protein of interest.
Establishing a stable protein-producing cell line
To establish a stable cell line, IgG-T-REx-XBP-1(s) cells
were seeded and grown at 30°C under 1 μg/mL DOX (or0 μg/mL DOX as control) for 42 days. The supernatant
was collected every seventh day and submitted to ELISA,
which showed stable specific IgG productivity around an
average of 80.2 ng/105 cells/mL by cells incubated with
DOX compared to the basal level (25.7 ng/105 cells/mL
in cells without DOX) (Figure 6A). Moreover, the viable
cell density of IgG-T-REx-XBP-1(s) cells under 1 μg/mL
DOX was lower than cells without DOX for 42 days
(Figure 6B), which allowed cells to be kept in the same
AB
C
Figure 4 FACS analysis. The samples were run through the flow cytometer until 10.000 events were collected using no gate. The IgG-T-Rex-XBP-1(s)
cells were grown under induction with 0 μg/mL, 0.1 μg/mL, 0.5 μg/mL or 1 μg/mL DOX (on DOX induction, treated (t)) for seven days at 30°C. Then,
cells from each group were washed with DOX-free media and grown in DOX-free media for seven more days at 30°C (off DOX induction, washed (w)).
The cells from each group were stained with ER-tracker™ green dye, and cell counts vs. ER-Tracker™ signal from IgG-T-REx-XBP-1(s) cells were measured
(on DOX induction, treated (t) (A) and off DOX induction, washed (w) (B)). Median fluorescence intensity (MFI) of ER-Tracker™ Green Dye from
IgG-T-REx-XBP-1(s) cells (on DOX induction, treated (t) and off DOX induction, washed (w) (C)).
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A B
Figure 5 FACS and Western analyses. Median fluorescence intensity measurements of mouse FITC anti-human IgG ligated to the tested IgG
(produced by IgG-T-REx-XBP-1(s) cells under DOX induction at 37°C and 30°C (and rituximab, control) that were previously incubated with Raji
cells) (A). Western blot analysis of IgG produced by IgG-T-REx-XBP-1(s) cells at 37°C and 30°C under DOX induction (PL, protein ladder) (B).
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scribed approach might be useful for the production of
recombinant secreted proteins, as cells growing under
the combination of DOX induction and low temperature
multiply more slowly but are more productive.A
B
Figure 6 Specific IgG productivity (A) and viable cell density (B) of th
DOX, control) for 42 days at 30°C. Error bars represent the standard dev
independent culture samples per group in two independent experiments,Conclusion
Many studies have been published on improving recom-
binant protein production. In general, the published data
suggest that the optimization of the production of spe-
cific target proteins requires specifically adjusted growthe IgG-T-REx-XBP-1(s) cells under 1 μg/mL DOX induction (0 μg/mL
iation of the mean of double determination from each of two
n = 4.
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study, we optimized the conditions for IgG (human anti-
CD20) specific productivity in CHO-K1 cells. We showed
that the combination of low temperature (30°C) and
XBP-1(s) overexpression regulated by DOX induction
significantly improved anti-CD20 specific productivity:
under 1 μg/mL DOX treatment, specific IgG productiv-
ity was increased by 32% compared to the cells grown
under the same concentration at 37°C and 74% compared
to the cells grown without DOX induction at 37°C or 30°C.
Moreover, the results of our study indicate the direct
dependence of specific IgG productivity on the concen-
tration of DOX (under 0.5 μg/mL, the increase was 2.7-
fold, and under 1 μg/mL, the increase was 3.9-fold),
which allows for the precise regulation of specific IgG
productivity in CHO-K1 cells. In addition to the con-
centration dependence, we demonstrated the possibility
of returning the specific IgG over productivity to the
basal level of specific productivity by removing DOX.
This step also restored the viable cell density, which
permitted the cells to overcome the problem of accu-
mulation of the target protein. In the production of pro-
teins, it may be possible to use the T-Rex-XBP-1(s)
system to turn up and down the production of protein,
repeating this cycle several times to accumulate higher
amounts of target protein without a loss of cell viability.
We also observed a DOX concentration-dependent
relationship involving XBP-1(s) overexpression (western
analysis), ER size expansion (FACS measurements) and
specific IgG productivity (ELISA). Finally, our data dem-
onstrate that it is possible, under DOX induction at low
temperature, to produce a target protein for an extended
period of time. Taken together, our data suggest the
T-REx-XBP-1(s) system can be used in CHO-K1 cells
for human immunoglobulin production.
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